Metronomic scheduling of trofosfamide chemotherapy in human NSCLC xenografts highly increases therapeutic efficacy compared to conventional scheduling by inhibition of angiogenesis.

International journal of clinical pharmacology and therapeutics

Volumn 42, Issue 11, 2004, Pages 652-653

  Stolting S ^a   Klink, T ^a   Bela, C ^a   Engels, C ^a   Wagner, T ^a  

^a Medizinische Klinik 1   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CYCLOPHOSPHAMIDE; DRUG DERIVATIVE; TROFOSFAMIDE;

ANIMAL; ARTICLE; CELL CULTURE; DRUG ADMINISTRATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 16644393421     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP42652     Document Type: Article

References (0)